arrow
J

John Thornhill

GlaxoSmithKline
H指数:21
被引数:4,157

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Month 12 outcomes of switching to long-acting cabotegravir plus rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study

SOLAR三期b阶段随机对照研究中,换用长效卡博格韦与利匹韦林联合口服引导方案(oral lead-in)与继续使用毕克格韦/恩曲他滨/替诺福韦艾拉酚胺方案后的12个月结局。

2025-12-010
OAAI
Rapid antiretroviral therapy in primary HIV-1 infection enhances immune recovery

原发性HIV-1感染的快速抗逆转录病毒治疗可增强免疫恢复

AIDS
IF3.1
2023-12-211
OA
Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series

在2022次暴发期间,女性和非二元人群中的人类猴痘病毒感染: 全球病例系列

LANCET
IF88.5
2022-12-0188
OAAI
Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption
2022-08-305
OAAI
Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022

猴痘病毒在16个国家的人类感染-2022年4月到6月

2022-08-251.3K
OA
HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells

HIV-1 Vpr在静息记忆T细胞的选择性感染过程中驱动组织驻留样表型

2022-04-017
OAAI
Human MAIT cells respond to and suppress HIV-1

人类MAIT细胞响应并抑制HIV-1

2021-12-2423
PRE
Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report
2020-05-01161
OAAI
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial
LANCET
IF88.5
2020-03-01100
OAAI